Poxel SA(POXEL)

Description: Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic diseases, type 2 diabetes, and liver diseases. The company's lead product is TWYMEEG (Imeglimin), an oral drug candidate that targets mitochondrial dysfunction and approved for the treatment of type 2 diabetes in Japan. It also develops PXL770, an adenosine monophosphate-activated protein kinase enzyme, which is in a Phase 2a clinical trial that treats chronic metabolic diseases, including diseases that affect the liver, such as non-alcoholic steatohepatitis (NASH). Poxel S.A. has a licensing agreement with Enyo Pharma S.A.S. for the development of farnesoid X receptor that is in Phase 2a study for the treatment of hepatitis B and NASH; and DeuteRx LLC for the development of PXL065, a mitochondrial pyruvate carrier inhibitor, which is in a phase I clinical trial for the treatment of NASH. The company was incorporated in 2009 and is headquartered in Lyon, France.

---

Keywords: Medicine Biopharmaceutical Disease Diabetes Hepatitis Hepatitis B Liver Disease Metabolic Disease Steatohepatitis Non Alcoholic Fatty Liver Disease Adenosine Kinase Obeticholic Acid Treatment Of Hepatitis B Mitochondrion Mitochondrial Dysfunction Tropifexor

---

Home Page: www.poxelpharma.com

Immeuble Le Sunway
Lyon, 69007
France
Phone: 33 4 37 37 20 10

---

Officers

Exchange: PA

Country: FR

Currency: Euro (€)